F2G
Karen Cornelissen has work experience as the Director of Early Clinical Development at F2G since February 2017. Prior to that, they worked at Covance as a Scientific Director since 1999.
Karen Cornelissen has a Bachelor of Science (BSc) degree in Pharmacology from Portsmouth Polytechnic. Karen also pursued further education in the field of Drug Metabolism and obtained a Doctor of Philosophy (PhD) degree from the University of Bath.
F2G
1 followers
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.